Please  note that there will be no Saturday walk in July 1st 

PLEASE PRINT AND COMPLETE  FOR  ALL  CHILDREN and CAREGIVERS RECIEVING INFLUENZA VACCINES.     

PLEASE BRING IT ALONG WITH OHIP INFORMATION WITH YOU FOR THE VISIT

FAILURE TO HAVE A COMPLETED FORM WITH YOU MAY RESULT IN A DELAY FOR YOU GETTING THE VACCINATION !

                    Click here for link to PATIENT INFORMATION  & CONSENT FORM FOR INFLUENZA CLINICS

Seasonal Influenza Vaccination Clinics

2016-2017

We continue to encourage influenza immunization for our patients and families.

This year you will have a choice of influenza immunizations for your child to receive. These choices of influenza immunization are depending on your child’s age.   Please read carefully so you can make an informed decision.

If your child is age 6months to  2 years of age:

         If your child is 6 months to 2 years of age, we will administer Quadrivalent inactivated vaccine (QIV) via intramuscular injection.

         QIV is provided by the Ministry of Health and there is no cost to the family. 

         If your child has not received a previous flu vaccine then he or she will require 2 doses of QIVgiven 1-2 months apart. 

         QIV  cannot cause Influenza or other viral illness as there are no live components to these vaccines.

         QIV  should not be administered to persons with known hypersensitivity to components of the vaccines or those with chicken or egg  hypersensivity without  consultation by their doctor.  They should not be given to children having acute febrile illness or untreated asthma .  

If your child is 2 years of age or older :

         If your child is 2 years of age or older he or she will receive QIV via intranasal mist  OR via intramuscular injection.   Both of these vaccines are given at no cost to the patient.   

         If your child has not received a previous flu vaccine then he or she will require 2 doses of  the  influenza vaccine  1-2 months apart. 

            If there has been a previous flu vaccination only one dose is given.

         Influenza vaccines should not be administered to persons with known hypersensitivity to components of the vaccines or those with chicken or egg  hypersensivity without  consultation by their doctor.  They should not be given to children having acute febrile illness or untreated asthma .  

Detailed information about seasonal flu and immunization is available at

https://www.ontario.ca/page/kids-and-flu-shot

Watch Protect your Family From  the Flu , a short animated video for families which helps to explain important reasons to get the Flu vaccine and addresses  some common myths about it . 

Important points include :

                       Vaccine recommended for all Ontario citizens greater than 6 months of age

                       Strong recommendation for all children 6months to 5 years of age in day care 
and preschool

                       Strong recommendation for all children with chronic respiratory problems 
including asthma

                       Strong recommendation for all children with heart problems, immunity disorders, 
children on steroids , with kidney disease and other chronic health conditions

                       Strong recommendation for family members and care givers of infants less than 
6 months of age and those who will give birth during the influenza season

              Previously unvaccinated children less than 9 years of age require two doses of 
Influenza vaccine with a minimum interval of four weeks between doses. Those who have been previously vaccinated with influenza vaccine are recommended to receive one dose. 
Influenza vaccination will be available at the Vaughan Pediatric Clinic during your child’s regular scheduled appointments and on special Influenza vaccine clinic dates. Flu vaccine clinics are held without appointment on a first come first served basis, only on the dates specified. Caregivers will be encouraged to receive Influenza vaccine along with their children.

It is mandatory for all vaccine recipients to present valid health cards on arrival.

You must print and complete  a  Patient information and consent form for each person to be vaccinated .  You and your child will not receive flu vaccine without prior completion of the form.  Please present the completed for upon your arrival .      

For a list of our  Influenza Vaccine dates  click here      

2016  Influenza vaccine clinic dates and times:

Saturday December 3

Saturday December 10

In order  to improve  on flow of patients and hopefully minimize your own waits in lineups  we will be staggering registration times   according to last  names .  Please have OHIP  information ready and a  signed patient information/ consent form for all patients receiving vaccine.   Consent forms  are  available on our website or by clicking here

            Patients last name beginning with letter A to H    register  9-10 am

            Patients last  name beginning with letter  I to P   register  10- 11 am

            Patients last name beginning with letter  Q to Z  register   11- 12

Future Flu vaccine  clinic dates will  be updated.  Continue to monitor this page for updated  information .

Infants and Children who have recieved  their  first dose of Influenza Vaccine this year requre a booster dose 1-2 months later.    

Sanofi Canada Issues Voluntary Nationwide Recall of Allerject^® 
Due to Potential Inaccurate Dosage Delivery

FOR IMMEDIATE RELEASE

Laval, Quebec – October 28^th, 2015 - Sanofi-aventis Canada Inc. (Sanofi Canada) is recalling all Allerject^® (epinephrine injection, USP). The voluntary recall involves all Allerject currently on the market and includes both the 0.15 mg/ 0.15 mL and 0.3 mg/0.3 mL strengths for hospitals, retailers and consumers. The products have been found to potentially have inaccurate dosage delivery.

If a patient who is experiencing a serious allergic reaction (i.e., anaphylaxis) did not receive the intended dose, there could be significant health consequences, including death because anaphylaxis is a potentially life-threatening condition.

As of October 26, 2015, Sanofi US and Canada have received 26 reports of suspected device malfunctions from an estimated 2,784,000 units distributed in North America. 

Specifically, in Canada, 9 suspected device malfunctions were reported out of an estimated 492,000 units distributed. None of these device malfunction reports have been confirmed. In these reports, patients have described symptoms of the underlying hypersensitivity reaction. No fatal outcomes have been reported among these cases.  

Allerject (epinephrine injection, USP) is used to treat life-threatening allergic reactions (anaphylaxis) in people who are at risk for or have a history of these reactions. All Allerject units are being recalled.

Sanofi Canada is proactively communicating with wholesalers, pharmacists, patients and caregivers, patient associations, and hospitals to inform them of this precautionary voluntary recall and how to proceed.

Sanofi Canada is actively working with suppliers of alternative epinephrine auto-injectors to have a full stock available in Canada as soon as possible.  

Canadian customers are asked to immediately return the product to their local pharmacy to obtain an alternate epinephrine auto-injector. In the absence of availability of an alternate epinephrine auto-injector, patients are instructed to retain their Allerject device until an alternate auto-injector is available.

In light of the need to manage supply associated with this recall, we are asking customers and pharmacists to limit the replacement of Allerject to one unit or the appropriate number of units as instructed by your healthcare professional until full alternative stock is available. 

If patients are unable to obtain supplies of alternative epinephrine auto-injectors, and in the event of a life-threatening allergic reaction (anaphylaxis), patients who do not have a replacement product should use their Allerject device, call 911 and immediately seek emergency medical services, in accordance with current product labelling.

Sanofi Canada is committed to patient safety and the quality of Allerject, and will continue to work closely with our partners and regulatory authorities to resolve this issue in a timely manner.

Any questions or concerns regarding this voluntary product recall, please contact the Allerject Call Center at 1-855-405-4321.

Any adverse events that may be related to the use of these products should be reported either to:

Sanofi Canada

Phone:             1-855-405-4321

Health Canada

Phone:             1-866-234-2345

MedEffect Canada website: 

http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php

This recall is being conducted with the knowledge of Health Canada.

Important Safety Information
Indication

Allerject® is indicated for the emergency treatment of anaphylactic reactions in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.

Meningococcal ACWY  (Menactra/Menveo)  is given to Ontario teenagers at no cost in grade 7 .  Invasive  Meningococcal Disease (IMD) is an important cause of sudden onset bacterial blood infections (Septicemia)  leading to Meningitis , disability and death.    IMD mortality is approximately 10%.  Of  IMD survivors 10-20% have long term sequelae including hearing loss, neurologic disabilities and digit or limb amputations Teenagers  and young adults are high risk age groups for this bacterial infection.   

The Centre for Disease  control  recommends a dose of Menactra/Menveo to be given in Grade 7 and  a booster dose in Grade 12 to  boost immunity post secondary school .  We agree and recommend a second  dose of Menactra/Menveo as a booster in Grade 12.  It is not covered by OHIP and is available for a fee at our office. 

Please  call our office and book an appointment  to recieve  a Meningococcal ACWY (Menactra/Menveo) booster.

-return to Vaccination for teenagers - our recommendations-

Invasive Meningococcal Disase (IMD) is an important cause of death and disability for which teenagers and young adults are at particular risk.  IMD mortality is approximately 10%.  Of  IMD survivors 10-20% have long term sequelae including hearing loss, neurologic disabilities and digit or limb amputations .  In Canada, IMD is caused by the two most prominent strains -  B and C strains.   Other vaccine preventable strains are A, W and Y strains.  

Meningococcal ACWY (Menactra/Menveo) is given to Ontario teenagers at no cost in grade 7.   We also encourage a booster of Meningococcal ACWY   in grade 12.  

Meningococcal B vaccine (Bexsero) Is recomenneded to prevent IMD caused by B strain  which is the most common strain leading to IMD in Canada.     We  encourage immunization against Meningococcal B strain to all teenagers age 15  and older.  It is not currently paid for by OHIP  and is available for private purchase in our office.    

Please call our office to book an appointment to recieve Meningococcal B vaccine

-return to Vaccination for teenagers - our recommendations-